DK0993304T3 - Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat - Google Patents
Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivatInfo
- Publication number
- DK0993304T3 DK0993304T3 DK98925873T DK98925873T DK0993304T3 DK 0993304 T3 DK0993304 T3 DK 0993304T3 DK 98925873 T DK98925873 T DK 98925873T DK 98925873 T DK98925873 T DK 98925873T DK 0993304 T3 DK0993304 T3 DK 0993304T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical composition
- side effects
- acid derivative
- hydroxamic acid
- reduced side
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- LEAWDHURBAHMCQ-UHFFFAOYSA-N (2-hydroxy-3-piperidin-1-ylpropyl) pyridine-3-carboxylate Chemical compound C1CCCCN1CC(O)COC(=O)C1=CC=CN=C1 LEAWDHURBAHMCQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9701081A HU9701081D0 (en) | 1997-06-23 | 1997-06-23 | Pharmaceutical composition of antitumoral activity |
| PCT/IB1998/000961 WO1998058676A1 (en) | 1997-06-23 | 1998-06-22 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0993304T3 true DK0993304T3 (da) | 2003-07-28 |
Family
ID=89995266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98925873T DK0993304T3 (da) | 1997-06-23 | 1998-06-22 | Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6440998B1 (cs) |
| EP (1) | EP0993304B1 (cs) |
| JP (1) | JP2002508762A (cs) |
| KR (1) | KR20010020496A (cs) |
| CN (1) | CN1127984C (cs) |
| AT (1) | ATE235918T1 (cs) |
| AU (1) | AU735922B2 (cs) |
| BR (1) | BR9810312A (cs) |
| CA (1) | CA2294913C (cs) |
| CZ (1) | CZ298468B6 (cs) |
| DE (1) | DE69812949T2 (cs) |
| DK (1) | DK0993304T3 (cs) |
| ES (1) | ES2195344T3 (cs) |
| HU (1) | HU9701081D0 (cs) |
| IL (1) | IL133508A (cs) |
| NO (1) | NO322206B1 (cs) |
| NZ (1) | NZ502039A (cs) |
| PL (1) | PL191718B1 (cs) |
| PT (1) | PT993304E (cs) |
| RU (2) | RU2254129C2 (cs) |
| SK (1) | SK282877B6 (cs) |
| TR (1) | TR199903214T2 (cs) |
| UA (1) | UA64757C2 (cs) |
| WO (1) | WO1998058676A1 (cs) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884424B2 (en) * | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| EP1615646B2 (en) | 2003-04-08 | 2022-07-27 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| JP5241484B2 (ja) * | 2005-03-07 | 2013-07-17 | ザ ユニヴァーシティー オヴ シカゴ | 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用 |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| US7763601B2 (en) * | 2006-11-02 | 2010-07-27 | N-Gene Research Laboratories, Inc. | Prevention and treatment of obesity |
| US20080108602A1 (en) * | 2006-11-02 | 2008-05-08 | N-Gene Research Laboratories, Inc. | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication |
| JP5461386B2 (ja) | 2007-03-29 | 2014-04-02 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 末梢オピオイド受容体アンタゴニストおよびその使用 |
| MX351611B (es) * | 2007-03-29 | 2017-10-20 | Wyeth Llc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| SI2139890T1 (sl) | 2007-03-29 | 2014-12-31 | Wyeth Llc | Antagonisti perifernih opioidnih receptorjev in njih uporaba |
| CA2704128A1 (fr) * | 2007-10-30 | 2009-07-30 | Trophos | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux |
| WO2009074835A1 (en) * | 2007-12-10 | 2009-06-18 | N-Gene Research Laboratories Inc. | Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity |
| JP5358587B2 (ja) * | 2008-02-06 | 2013-12-04 | プロジェニックス・ファーマシューティカルス・インコーポレイテッド | （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途 |
| WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
| ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
| ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
| HUP1100445A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| HUP1100444A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| RU2522548C2 (ru) * | 2012-09-26 | 2014-07-20 | Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) | Ингибитор уридинфосфорилаз |
| US9938279B2 (en) * | 2013-04-09 | 2018-04-10 | Energenesis Biomedical Co., Ltd | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) |
| CN108703970A (zh) * | 2013-09-18 | 2018-10-26 | 华安医学股份有限公司 | 一种活化ampk的化合物及其用途 |
| MA45334A (fr) | 2016-03-24 | 2019-01-30 | Probiotical Spa | Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes |
| RU2679136C1 (ru) * | 2018-03-13 | 2019-02-06 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) | Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном |
| HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4308399A (en) * | 1977-08-30 | 1981-12-29 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| HU207988B (en) * | 1988-10-20 | 1993-07-28 | Biorex Kutato Fejlesztoe Kft | Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components |
| HUT54347A (en) * | 1989-01-10 | 1991-02-28 | Chinoin Gyogyszer Es Vegyeszet | Improved process for producing amidoximes |
| JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
| NZ265164A (en) * | 1993-03-31 | 1997-09-22 | Merck & Co Inc | Pharmaceutical composition comprising a pyridinyl-methyl-piperazine derivative and any of azt, ddi or ddc |
| TW381025B (en) * | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| HU9502843D0 (en) * | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| UA64716C2 (en) * | 1996-08-09 | 2004-03-15 | Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells |
-
1997
- 1997-06-23 HU HU9701081A patent/HU9701081D0/hu unknown
-
1998
- 1998-06-22 PT PT98925873T patent/PT993304E/pt unknown
- 1998-06-22 AT AT98925873T patent/ATE235918T1/de not_active IP Right Cessation
- 1998-06-22 WO PCT/IB1998/000961 patent/WO1998058676A1/en not_active Ceased
- 1998-06-22 SK SK1764-99A patent/SK282877B6/sk not_active IP Right Cessation
- 1998-06-22 IL IL13350898A patent/IL133508A/xx not_active IP Right Cessation
- 1998-06-22 KR KR1019997012198A patent/KR20010020496A/ko not_active Ceased
- 1998-06-22 EP EP98925873A patent/EP0993304B1/en not_active Expired - Lifetime
- 1998-06-22 JP JP50404999A patent/JP2002508762A/ja not_active Withdrawn
- 1998-06-22 ES ES98925873T patent/ES2195344T3/es not_active Expired - Lifetime
- 1998-06-22 NZ NZ502039A patent/NZ502039A/xx unknown
- 1998-06-22 TR TR1999/03214T patent/TR199903214T2/xx unknown
- 1998-06-22 DK DK98925873T patent/DK0993304T3/da active
- 1998-06-22 BR BR9810312-1A patent/BR9810312A/pt active Search and Examination
- 1998-06-22 AU AU77837/98A patent/AU735922B2/en not_active Ceased
- 1998-06-22 RU RU2003101319/15A patent/RU2254129C2/ru not_active IP Right Cessation
- 1998-06-22 CA CA002294913A patent/CA2294913C/en not_active Expired - Fee Related
- 1998-06-22 US US09/446,064 patent/US6440998B1/en not_active Expired - Fee Related
- 1998-06-22 CZ CZ0462599A patent/CZ298468B6/cs not_active IP Right Cessation
- 1998-06-22 CN CN98807103A patent/CN1127984C/zh not_active Expired - Fee Related
- 1998-06-22 UA UA2000010341A patent/UA64757C2/uk unknown
- 1998-06-22 RU RU2000102359/14A patent/RU2214238C2/ru not_active IP Right Cessation
- 1998-06-22 PL PL337719A patent/PL191718B1/pl unknown
- 1998-06-22 DE DE69812949T patent/DE69812949T2/de not_active Expired - Fee Related
-
1999
- 1999-12-20 NO NO19996349A patent/NO322206B1/no unknown
-
2002
- 2002-02-28 US US10/084,183 patent/US6656955B2/en not_active Expired - Fee Related
- 2002-02-28 US US10/084,095 patent/US6838469B2/en not_active Expired - Fee Related
- 2002-03-27 US US10/106,227 patent/US6720337B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0993304T3 (da) | Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat | |
| NO970894L (no) | Farmasöytiske preparater inneholdende et gallesalt og en buffer for ökt biotilgjengelighet av en aktiv forbindelse | |
| GR3034204T3 (en) | Lipopolyamines as transfection agents and pharmaceutical uses thereof | |
| CY1112274T1 (el) | Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν | |
| NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
| PT1123120E (pt) | Formulacao medicinal em aerossol | |
| TR200100894T2 (tr) | Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları. | |
| BR9809304A (pt) | "formulações de proteìna c ativada" | |
| MA26458A1 (fr) | Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent. | |
| MY118151A (en) | Pharmaceutical formulations containing voriconazole. | |
| CA2171275A1 (en) | Stilbene derivatives and pharmaceutical compositions containing them | |
| FI832355A0 (fi) | 9-(2-hydroxyetoximetyl)guanidin-derivat | |
| WO2000045800A3 (en) | Immunosurpressive effects of pteridine derivatives | |
| PL346764A1 (en) | New oral formulation for 5-ht4 | |
| IL131216A0 (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| TR200002766T2 (tr) | 3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri | |
| TR200002767T2 (tr) | Makrolit LHRH Antagonistleri | |
| MA26788A1 (fr) | COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION | |
| MX9709453A (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion. | |
| ZA981079B (en) | Amino acid ester containing azole antifungals. | |
| RU94040865A (ru) | Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью | |
| CA2182812A1 (en) | Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide | |
| TR200102196T2 (tr) | Mono-asiloksi aralkil nöromuskular relaksanları. | |
| MY152490A (en) | New oral formulation |